Linked Life Data

7884399

Source:http://linkedlifedata.com/resource/pubmed/id/7884399

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1995-4-13
pubmed:abstractText
Attempts to lessen the progression of Parkinson's Disease (PD) have made use of 2 strategies: inhibition of monoamine oxidase type B with deprenyl (selegiline) and the free radical trapping agent alpha-tocopherol (vitamin E). Clinical trials exploring these possibilities have suggested that deprenyl can alter the natural course of PD, although the mild symptomatic effects produced by this drug confound the analysis of its possible protective actions. Alpha-tocopherol conferred no neuroprotection. Since deprenyl produces a variety of pharmacological effects, the results of the DATATOP and related clinical studies with this drug are subject to several alternative explanations.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0303-6995
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
171-81
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
pubmed:affiliation
Clinical Neuroscience Center, School of Medicine, Wayne State University, West Bloomfield, MI.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review